Neel Radhakisan Lahoti

Neel Radhakisan Lahoti

Active Director Whole-Time Director DIN 03415564
DIN 03415564 First appointment Apr 2011 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Apr 2011
Shareholding value •••• Premium profile

About Neel Radhakisan Lahoti

Data last updated:

Neel Radhakisan Lahoti is a Whole-Time Director at Synergen Bio Private Limited (since 2018), Director at Nycg Buildcon Private Limited (since 2022) and Director at Coldray Plasma Labs Private Limited (since 2025). The companies operate in Pharma, Real Estate and Construction and Healthcare. The 2 current companies with reported revenue have a combined latest revenue of ₹36.37 Cr; the largest is Synergen Bio Private Limited at ₹36.01 Cr (FY 2024). Earlier, Neel Radhakisan Lahoti was a Director at Sarla Pharma Private Limited (from 2011) and Director at Novus Labs Private Limited (from 2015).

DIN 03415564
Primary Designation Whole-Time Director
Industry Pharma
First Appointment 06 Apr 2011
Oldest Company Age 15 yrs
Largest company Synergen Bio Private Limited · ₹36.01 Cr (FY 2024)
Combined revenue ₹36.37 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Synergen Bio Private Limited U74999PN2018PTC177201
Whole-Time Director14 Jun 20182018₹36.01 Cr (FY 2024)Active
Nycg Buildcon Private Limited U45202PN2022PTC216514
Director29 Nov 20222022₹35.5 Lakh (FY 2024)Active
Coldray Plasma Labs Private Limited U32509PN2025PTC238649
Director25 Feb 20252025Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sarla Pharma Private Limited U24239PN2011PTC139105
Director06 Apr 20112011Strike Off
Novus Labs Private Limited U24299PN2015PTC154616
Director07 Apr 20152015Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Neel Radhakisan Lahoti

Directorship timeline

Open interactive timeline →
Synergen Bio Private Limited
Sarla Pharma Private Limited
Novus Labs Private Limited
Nycg Buildcon Private Limited
Premium access

Shareholding and investment profile for Neel Radhakisan Lahoti

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Neel Radhakisan Lahoti

Neel Radhakisan Lahoti currently holds 3 directorships: Synergen Bio Private Limited (Whole-Time Director, since 14 Jun 2018, revenue ₹36.01 Cr (FY 2024)); Nycg Buildcon Private Limited (Director, since 29 Nov 2022, revenue ₹35.5 Lakh (FY 2024)); Coldray Plasma Labs Private Limited (Director, since 25 Feb 2025).

Neel Radhakisan Lahoti was first appointed on 06 Apr 2011 as Director at Sarla Pharma Private Limited. The most recent appointment on record is 25 Feb 2025 at Coldray Plasma Labs Private Limited.

The 2 current companies of Neel Radhakisan Lahoti that report revenue have a combined latest revenue of ₹36.37 Cr: Synergen Bio Private Limited ₹36.01 Cr (FY 2024); Nycg Buildcon Private Limited ₹35.5 Lakh (FY 2024).

Neel Radhakisan Lahoti held 2 earlier board appointments: Sarla Pharma Private Limited (Director, from 06 Apr 2011); Novus Labs Private Limited (Director, from 07 Apr 2015).

The current boards of Neel Radhakisan Lahoti's companies include Puneet Verma (Synergen Bio Private Limited), Sanjay Bhalchandra Phadnis (Coldray Plasma Labs Private Limited), Vrushal Sanjay Phadnis (Coldray Plasma Labs Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available